Update on CRC Screening

CAROLINE SOYKA, DO

DIRECTOR OF ENDOSCOPY; GEAUGA MEDICAL CENTER DIVISION OF GASTROENTEROLOGY ASSISTANT PROFESSOR OF MEDICINE

this year 50,000 PEOPLE are expected to DIE of colorectal cancer

Screening could SAVE more than HALF of those lives*

*American Cancer Society Cancer Facts & Figures 2013

find out how the other half LIVES ask your doctor about a COIONOSCOPY

> American College of Gastroenterology www.gi.org



Why talk about it?

One of the most preventable cancers!

2nd leading cause of cancer deaths
2nd most common cancer diagnosed in women
1 in 3 people diagnosed will die
Lifetime incidence (average risk): 4.4%

Nationwide: 147,500 new cases 57,100 deaths



Data represents 2003 colorectal cancer estimates from the SEER database

Women are...

- Diagnosed with colon cancer at rates EQUALLY as men
- Less likely to get screening than men

Does Screening Help?

Death rates from CRC are declining on average 2.7 percent each year between 2004 and 2013

A microsimulation model, MISCAN-Colon, suggests that screening may account for 53 percent of the observed reduction in CRC mortality

Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116:544.

Current GI Association Screening Guidelines: Who and When To Screen

- Average risk: start regular screening at age 50
- Begin screening of African Americans at age 45
- People who are in good health and with a life expectancy of more than 10 years should continue regular colorectal cancer screening through the **age of 75**.
- For people ages 76 through 85, the decision to be screened should be based on a person's preferences, life expectancy, overall health, and prior screening history.

Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc 2017; 86:18.

Current Screening Guidelines: Who and When To Screen

- *For screening, people are considered to be at average risk if they do not have:
 - A personal history of colorectal cancer or certain types of polyps
 - A family history of colorectal cancer
 - A personal history of inflammatory bowel disease (ulcerative colitis or Crohn's disease)
 - A confirmed or suspected hereditary colorectal cancer syndrome, such as familial adenomatous polyposis (FAP) or Lynch syndrome (hereditary non-polyposis colon cancer or HNPCC)
 - A personal history of getting radiation to the abdomen (belly) or pelvic area to treat a prior cancer

Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc 2017; 86:18.

Types of Colon Cancer



Current Screening Guidelines: Who and When To Screen

Family History

Recommended Screening Interval

Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc 2017; 86:18.

Current Screening Guidelines: Who and When To Screen

HNPCC (Lynch Syndrome)

Patients who meet the Bethesda criteria should undergo microsatellite instability testing of their tumor or a family member's tumor and/or tumor immunohistochemical staining for mismatch repair proteins (Grade 2 B)

Note: we reflexively test ALL tumors at UH for MSI

- Those with positive genetic testing, or those at risk when genetic testing is unsuccessful in an affected proband, should undergo colonoscopy every 2 years beginning at age 20 – 25 years,
- Endometrial cancer at a young age (<50)</p>

ACS Update 5/30/2018

Average risk: start regular screening at age 45

The Why (MISCAN Modeling)

- Microsimulation Screening Analysis-Colon (MISCAN-Colon) model was used to inform the US Preventive Services Task Force colorectal cancer (CRC) screening guidelines
- Life-years gained (LYG; benefit), the number of colonoscopies (COL; burden) and the ratios of incremental burden to benefit (efficiency ratio [ER] = ΔCOL/ΔLYG) were projected for different screening strategies.
 - These values were also corrected for life years lost due to screening complications
- Consequently, the balance of burden to benefit of screening improved and now 10-yearly colonoscopy screening starting at age 45 years resulted in an ER of 32

https://www.uspreventiveservicest askforce.org/Page/Document/ev aluating-test-strategies-forcolorectal-cancer-screening-adecision-analysis-for-the-uspreventive-services-taskforce/colorectal-cancerscreening A total of 132 unique screening strategies were evaluated

US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 2016; 315(23):2564-75. Copyright © 2016 American Medical Association

Lifetime number of colonoscopies and life-years gained (LYG) for colonoscopy screening strategies

9 efficient strategies identified

US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 2016; 315(23):2564-75. Copyright © 2016 American Medical Association

Why 45?

- It was efficient (1 of the 9)
- Highest # of LYG among the strategies with ERs <40 and 45</p>
- Compared with the current recommendation (screening every 10 years from ages 50-75 years), this strategy resulted in 25 (+6.2%) additional LYG

Peterse EFP, Meester RGS, Siegel RL, et al. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. Cancer 2018; 124:2964.

Screening Options

Direct Visualization

- Colonoscopy every 10 years
- CT Colonography every 5 years
- Flexible Sigmoidoscopy every 5 years
- Flexible Sigmoidoscopy every 10 years with FIT every year

US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 2016; 315(23):2564-75. Copyright © 2016 American Medical Association

Stool Testing

FOBT every year FIT every year Cologuard (Stool DNA) every 3 years

US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 2016; 315(23):2564-75. Copyright © 2016 American Medical Association

FIT vs Cologuard vs Colonoscopy

- 9989 patients enrolled and each underwent FIT, Cologuard AND colonoscopy
- <u>Cologuard:</u> sensitivity for CRC of 92%, 40% sensitivity for SSPs >1 cm in size
- FIT: 73.8% sensitivity for cancer, sensitivity for SSPs = to the false-positive rate, indicating no sensitivity.
- <u>Cost effectiveness</u>: many many modeling studies have been done, and they all show ALL screening tests are cost effective as cost of cancer treatment far outweighs cost of screening (for both colonoscopy AND stool based testing)

Imperiale TF, Ransohoff DF, Itzkowitz SH et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287–1297.

Cologuard

Covered by Medicare, every 3 years, age 50-85, as a SCREEN

- ► If positive → need colonoscopy
- Cannot go back to Cologuard

Who CANNOT use Cologuard

•Patients with a history of colorectal cancer, adenomas, or other related cancers.

•Patients who have had a positive result from another colorectal cancer screening method within the last 6 months.

•Patients who have been diagnosed with a relevant familial (hereditary) cancer syndrome, such as Hereditary nonpolyposis colorectal cancer syndrome (HNPCCC or Lynch Syndrome), Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's syndrome, Turcot's (or Crail's) syndrome, Cowden's syndrome, Juvenile Polyposis, Cronkhite-Canada syndrome, Neurofibromatosis, Familial Hyperplastic Polyposis.

•Patients who have been diagnosed with a condition that is associated with high risk for colorectal cancer. These include but are not limited to:

- Inflammatory Bowel Disease (IBD)Chronic ulcerative colitis (CUC)
- Crohn's disease
- Familial adenomatous polyposis (FAP)
- Family history of colorectal cancer**

Colonoscopy

Get the polyp. Get the cure.

Advantages

- Detects >95% polyps and 100% cancers
- Provides diagnosis and <u>therapy</u>
- Medicare covers average-risk

Limitations

- ► Risks
- Availability
- ► Cost
- ► Compliance



Source: Amersi F et al. Clin Colon Rectal Surg. 2005;18(3):133-140; 2. Rozen P, Young G, Levin B, et al. Colorectal Cancer in Clinical Practice, Prevention, Early Detection and Management, Second Edition. CRC Press; 2006.

Adenoma-Carcinoma Sequence

- Most colorectal cancers (CRCs) arise from adenomas
- The progression from adenoma to carcinoma takes about 10 years
- Removal of adenomatous polyps prevents cancer
 - The National Polyp Study followed 1418 patients in whom colonoscopic examination led to the removal of one or more polyps.
 - During a mean follow-up of six years, the incidence of colon cancer was 88 to 90 percent lower than in patients reported in other studies who had polyps that were not removed and 76 percent lower than in the general population.

Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329:1977.

Benefits of Screening

Five-Year Relative Survival Rates for Colorectal Cancer by Stage at Diagnosis, 1995-2000

Polypectomy prevents cancer

BUT

90% survival if cancer found early



Is your provider doing a good job?

Table 3. Tools for patients to enhance colonoscopy quality

Questions for patients to ask prospective colonoscopists to help ensure a high-quality examination

- What is your adenoma detection rate? (should be ≥25% overall or ≥30% for male patients and ≥20% for female patients)
- 2. What is your cecal intubation rate (should be \geq 95% for screening colonoscopies and \geq 90% overall)
- Do you use split-dosing of bowel preparations? (effective bowel preparation requires that at least half the preparation be ingested on the day of the colonoscopy)

Checks of the endoscopy report after the procedure

- Does the report include photographs of the end of the colon, including the appendiceal orifice and ileocecal valve/terminal ileum? (this demonstrates that the full extent of the colon was examined)
- Is the bowel preparation quality described? (the preparation must be adequate to ensure effective examination)

SEE HOW A SMALL DIFFERENCE can make all the difference

Did you know that your risk of colon cancer increases dramatically after the age of 50? But with regular screening, over 90% of cases can be stopped before the cancer advances³

If detected early, colon cancer is highly treatable.4



*Based on 5-year survival rate

Are people getting tested?

Testing rates remain far too low

Fewer than half of Americans over age 50 report having had a recent colorectal cancer screening test

Because of low testing rates, only 39% of colorectal cancers are detected at the earliest, most treatable stage

~							
🕞 🕘 🏉 http://aemr.	r.uhhospitals.org/ahsweb/ 오 - ৫ 🧭 Allscripts ×	SOYKA, CAROLINE					
File Edit View Favor	🛛 🖷 Add Clinical Item						
Provider 💼 Break I Chart 🔽 Daily Clinic	SOYKA, Caroline 19-Nov-1985 (32y) F	AUDIT: 17-Oct-2018					
SOYKA, CARO	🔲 🕂 🔨 🛛 History Builder 🖉 🔿	rders 🗐 🔂					
Select Patient 🕶 🧾 🔮 🍙		ed Admin Immun Lab Rad Procs Findings FU/Ref					
Worklist Desktop View	Active Problem Vy Priority VS B V C						
	Name ICD-9						
		My Favorites OFF Record w/o Ordering					
CVM Research Scr	r ⊟ Health Maintenance/Risks ≣ ■ BRAVO Placement Only (No	(EGD)					
Patient Worklist Problem	Other Problems Endoscopy - Upper Gl						
Order-Result Mana 🔻	Acute otitis media 382.9 I ERCP	B L V					
0 Items : 30 Active Patient Task There							
	Image: Image	est C M W					
	Blood in stool 578.1 I Hydrogen Breath Test for B						
	Elevent de Cluster headache 339.00 Video Capsule Endoscopy						
	Encounter for birth control pills V25.41	F P Z					
		(a) Q					
	New Edit CareGuide Resolve	HR					
	* Medications	I S					
	Vorders Allergies						
	DUR Alerts: Drug-Drug (0) PAR (0) Disease (0) Dup Therapy (0) Dose (0)						
		OK Cancel					
Verify Annotate	e Authorize Authorize All New • Edit Print Requisition	Complete On Complete Today					

					a x
(\Leftrightarrow)	🖷 Order Details			rmale 71836287	☆ ☆
File	SOYKA, Caroline	19-Nov-1985 (32y) F	AUDIT: 17-Oct-2018		
Provider Chart	🖽 🗰 Colone	oscopy 👔		AUDIT: 17-Oct-2018	<u>k</u> X Logoff alcs
SO	For:	[1] Encounter for screening colonoscopy	¥		
Select		Active Details	X	Rad Procs Findings FU/Ref	
Wor	To Be Done:	170ct2018	i s	5 1	
				OFF E Record w/o Ordering	۲
-	Order Results		ecord w/o Ordering	τ τ τ	
Pat	Details Question	ns Add'I Details Charging Encounters History Annotations	*	AKU	
Orde	Perform :	Geauga Medical Center -	1	BLV	
		Ahuja Medical Center	Print Copy	CMW	
	Ordered By: 🖲	Bainbridge Health Center		DNX	
	Supervised By:	Geauga Medical Center Lyndhurst Surgery Center	Not Required	EOY	
	Managed By:	Mentor Medical Center Non UH Facility		F P Z	
	CC Results	Rainbow Babies and Children's Hospital Richmond Medical Center Gl			
		St. Johns Medical Center (Non-Interfaced) UH Amherst Health Center (Non-Interfaced) UH Avon Health Center (Non-Interfaced)		HR	
	Performing Instructions:	UH Chagrin Highlands Gastro DHI UH Cleveland Medical Center	Cite Result	<u> </u>	
	1000 Chars remaining	UH Conneaut Medical Center UH Elyria Medical Center (Non-Interfaced)			
	Patient	UH Geneva Medical Center UH North Ridgeville Health Center			
		UH Parma Medical Center UH Portage Medical Center (Non-Interfaced)	Save and Close ACI Cancel	OK Cancel	
L L		UH Samaritan Medical Center (Non-Interfaced) University Suburban Health Center (Non-Interfaced) Westlake Medical Center			
		vvesuake medical Center			

						p
$(\Rightarrow) ($	🖷 Order Details	;			, CAROLINE emale 71836287	7 1
File	SOYKA, Caroline	19-Nov-1985 (32y) F		AUDIT: 17-Oct-2018		
Provider Chart	🖽 🗰 Colon	ioscopy 🚯			AUDIT: 17-Oct-2018	×
SO						
Select	For:	[1] Encounter for screening colonoscopy	¥		Rad Procs Findings FU/Ref	
Worl	Status:	Active				
· ; 🔲 🔻	To Be Done:	170ct2018) 🗰 'S			
			Record w/o Ordering		OFF Record w/o Ordering	_
:	Order Results	Goals ns Add'I Details Charging Encounters			T [*] T	
Pat	Questions			*		
Orde		-			BLV	
0 Item	Colonoscopy Typ	e	Screening (30 Mins)		C M W	
	Sedation Type		•		DNX	
	Indications		Screening Colonoscopy			
	Indications				F P Z	
	Pre-existing Cond	litions	-	=	H R	
	Pre-existing Cond	litions	•		IS	
			A			
	Additional Informa	ation/Preferred Provider				
	GI Mental Compete	ence	Yes at mentally competent to provide consent	+		
			Save and <u>R</u> eturn to ACI Save and Close ACI	Cancel		
					OK Cancel	

My thoughts...

- Colon cancer is the second leading cause of cancer deaths in the U.S. yet it can be prevented by finding and removing precancerous polyps and the best way to find precancerous polyps is to perform screening colonoscopy on asymptomatic individuals
- The dilemma is that at least 40 percent of people eligible to be screened do not get screened. The reasons are numerous, including costs of time and money, access to care, not being aware of screening recommendations and, frankly, just not wanting to have a colonoscopy.
- If the detection rate of dangerous polyps is 42 percent, what is left unsaid is that 58 percent of the most dangerous polyps are not detected by Cologuard, and that is unacceptable.
- It is the last group of patients for which Cologuard is best suited. For people who just do not want to get a colonoscopy, knowing that it can prevent colon cancer, Cologuard is an option. 42 percent is much better than nothing.

COLON CANCER is:



Regular testing can prevent colon cancer or find it early. If you're 50 and older, go get tested!



THE OFFICIAL SPONSOR OF BIRTHDAYS!

cancer.org/fightcoloncancer

Also... many thanks to these OBs





